Sens. Kennedy and Enzi present drug safety bill

Share this article:
Outgoing Senate Finance Committee chair Chuck Grassley (R-IA) has written HELP Committee leaders with a laundry list of FDA shortcomings that he hopes they will address.

Sens. Edward Kennedy (D-MA) and Mike Enzi (R-WY) have re-introduced their Enhancing Drug Safety and Innovation Act to require better safety planning before a drug is approved, while improving FDA's response to risks identified after the drug is on the market. 

A release from Kennedy's office said the bill will:
• integrate safety issues and the approval process by requiring earlier and more focused consideration of safety issues;
• establish a flexible planning mechanism to obtain necessary safety info about each new drug;
• permit adaptation of the safety plan in response to new info; and
• bring fairness and timeliness
to the dispute resolution process.

Other key provisions cover:
• establishing a collaboration among FDA, academic research institutions, and the biomedical research industry to improve the process of drug development and evaluation and advance the FDA's critical path initiative;
• establishing a database of clinical trials to help enrollment in trials, provide a mechanism to track progress and ensure that the results are made public, and that patients, doctors and pharmacists have current info; and
• improving the FDA's screening of advisory committee members for financial conflicts of interest to ensure that these committees provide independent expert advice, and to bolster the credibility of the review process.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...